Description of Business and Summary of Significant Accounting Policies (Details Textual) |
1 Months Ended | 3 Months Ended |
|---|---|---|
Feb. 28, 2017 |
Mar. 31, 2017 |
|
| Description of Business and Summary of Significant Accounting Policies (Textual) | ||
| Dose escalation study description | Patients will be administered Actimab-M on day 1 at an initial dose of 0.5 µCi/kg and then assessed at day 42 for safety and efficacy. The dose can be increased to 1.0 µCi/kg or reduced to 0.25 µCi/kg based on safety assessment that will evaluate dose limiting toxicities (DLTs). Patients may receive up to 8 cycles of therapy but in no event will cumulative administration exceed 4.0 µCi/kg of Actimab-M. | |
| Machinery and equipment [Member] | ||
| Description of Business and Summary of Significant Accounting Policies (Textual) | ||
| Estimated useful lives | Three years | |
| Property and equipment depreciation method | Straight-line basis | |
| Furniture and fixtures [Member] | ||
| Description of Business and Summary of Significant Accounting Policies (Textual) | ||
| Estimated useful lives | Three years | |
| Property and equipment depreciation method | Straight-line basis |